Sinopsis
New and exciting data presented each day during the conference and address the potential impact on current clinical practice.
Episodios
-
A Guide to Pulmonary Arterial Hypertension (PAH) Diagnosis, Treatment, and Referral in Primary Care - Michael J. Bloch, MD
01/02/2020 Duración: 27minA Guide to Pulmonary Arterial Hypertension (PAH) Diagnosis, Treatment, and Referral in Primary Care
-
Managing Hyperkalemia With Novel Potassium Binders to Achieve Optimal Outcome - James J. Matera, DO, FACOI
01/02/2020 Duración: 42minManaging Hyperkalemia With Novel Potassium Binders to Achieve Optimal Outcome
-
Applying Appropriate Use Criteria for Cardiac Imaging: Improving CHD Screening and Diagnosis - David Wolinsky, MD, FACC, MASNC
01/02/2020 Duración: 42minApplying Appropriate Use Criteria for Cardiac Imaging: Improving CHD Screening and Diagnosis
-
Clinical Cases: MRD in Real-World Clinical Practice - Gail J. Roboz, MD; Ajai Chari, MD; Steven Coutre, MD; Prashant Kapoor, MD; Aaron C. Logan, MD, PhD
22/01/2020 Duración: 43minMRD in Hematologic Malignancies: Testing Considerations and Challenges
-
Chronic Lymphocytic Leukemia - Steven Coutre, MD
22/01/2020 Duración: 26minMRD in Hematologic Malignancies: Testing Considerations and Challenges
-
Multiple Myeloma - Ajai Chari, MD
22/01/2020 Duración: 19minMRD in Hematologic Malignancies: Testing Considerations and Challenges
-
Acute Myeloid Leukemia - Gail J. Roboz, MD
22/01/2020 Duración: 31minMRD in Hematologic Malignancies: Testing Considerations and Challenges
-
Acute Lymphocytic Leukemia: Overview of Latest Guidelines in Hematological Malignancies - Aaron C. Logan, MD, PhD
22/01/2020 Duración: 28minMRD in Hematologic Malignancies: Testing Considerations and Challenges
-
Game-Changing Potential of MRD in Hematological Malignancies - Prashant Kapoor, MD
22/01/2020 Duración: 34minMRD in Hematologic Malignancies: Testing Considerations and Challenges
-
CLL Case Discussions - Richard R. Furman, MD; Jennifer R. Brown, MD, PhD; Matt S. Davids, MD, MMSc; Neil E. Kay, MD; Kanti R. Rai, MD
31/12/2019 Duración: 49minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Immune Function in CLL: What is Wrong and Why? - Neil E. Kay, MD
31/12/2019 Duración: 30minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Panel Discussion: Next Line Treatment in CLL - Richard R. Furman, MD; Matthew S. Davids, MD; Thomas J. Kipps, MD; Jennifer R. Brown, MD, PhD
31/12/2019 Duración: 10minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Richter's: Who will Get, What to Do? - Jennifer R. Brown, MD, PhD
31/12/2019 Duración: 19minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Treatment for BTKi Progressors - Richard R. Furman, MD
31/12/2019 Duración: 20minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
NOTCH1: The Clinical and Basic Science Behind it - Silvia Deaglio, MD, PhD
31/12/2019 Duración: 13minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Update on CAR-T Cells in CLL - Thomas J. Kipps, MD, PhD
31/12/2019 Duración: 24minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Venetoclax Resistance: Mechanisms and Treatment Options - Matthew S. Davids, MD, MMSc
31/12/2019 Duración: 20minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Panel Discussion: Front-line CLL Treatment - Richard R. Furman, MD; Neil E. Kay, MD; Jennifer A. Woyach, MD; John N. Allan, MD
31/12/2019 Duración: 04minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Combination of Novel Agents: Is this the Final Answer? - John N. Allan, MD
31/12/2019 Duración: 24minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy
-
Novel Agents in Elderly CLL Patients: Should the Approach be Different? - Jennifer A Woyach, MD
31/12/2019 Duración: 20minFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy